Madrigal Pharmaceuticals, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William J. Sibold
- Full Time Employees
- 915
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1001 Conshohocken State Road West Conshohocken PA United States 19428
- IPO Date
- Feb 6, 2007
- CIK
- 0001157601
- Website
- madrigalpharma.com
- Similar Companies
- Business
- Madrigal Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative therapies for severe liver conditions. The company's primary focus lies in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), a disease with considerable unmet medical needs. Its leading therapeutic, Rezdiffra (resmetirom), an oral, liver-directed selective thyroid hormone receptor-β agonist, received accelerated approval from the U.S. Food and Drug Administration in March 2024 for adults with noncirrhotic MASH featuring moderate to advanced liver fibrosis. Rezdiffra has also secured approval from the European Commission for this indication. Madrigal continues to advance its clinical program, evaluating Rezdiffra in an ongoing Phase 3 outcomes trial for patients with compensated MASH cirrhosis. Additionally, the company is progressing an oral GLP-1 development candidate, MGL-2086, slated to enter clinical trials in early 2026, with potential for combination therapy alongside Rezdiffra. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Company News
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 1,800 Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact
Madrigal Appoints John C. Reed, M.D.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)